Search

Your search keyword '"HASSAN, MOUSTAPHA"' showing total 828 results
Start Over Author "HASSAN, MOUSTAPHA"
828 results on '"HASSAN, MOUSTAPHA"'

8. Tracking Stem Cells and Macrophages with Gold and Iron Oxide Nanoparticles-the Choice of the Best Suited Particles

Author

Sun, Xing, primary, Gamal, Mahmoud, additional, Nold, Philipp, additional, Said, Alaa, additional, Chakraborty, Indranath, additional, Pelaz, Beatriz, additional, Schmied, Franziska, additional, von Pückler, Kerstin, additional, Figiel, Jens, additional, Zhao, Ying, additional, Brendel, Cornelia, additional, Hassan, Moustapha, additional, Parak, Wolfgang J., additional, and Felivag, Neus, additional

Published
2024
Full Text
View/download PDF

10. List of contributors

Author

Agwamba, Ernest C., primary, Ahadian, Samad, additional, Ahmadi, Fatemeh Maghsood, additional, Ahmadian, Roohollah, additional, Akbari, Babak, additional, Akhtari, Negin, additional, Alarcin, Emine, additional, Alem, Halima, additional, Ancira-Cortez, Alejandra, additional, Aref, Amir Reza, additional, Avci-Adali, Meltem, additional, Ayran, Musa, additional, Azarian, Maryam, additional, Bal-Öztürk, Ayça, additional, Barabadi, Hamed, additional, Barati, Maedeh, additional, Bardouni, Mohammad Mahdi, additional, Barzegar, Sajjad, additional, Bilakaya, Besa, additional, Bozlar, Michael, additional, Bozorgchami, Negar, additional, Camlik, Gamze, additional, Cekuc, Mehmet Sertac, additional, Chakafana, Graham, additional, Chakraborty, Gulmi, additional, Chhikara, Nidhi, additional, Cruz-Nova, Pedro, additional, Davari-Kia, Kamyar, additional, De, Ranjit, additional, Degim, Ismail Tuncer, additional, Degim, Zelihagul, additional, Eivazzadeh-Keihan, Reza, additional, Ezati, Negin, additional, Farahani, Ehsan Ortegoli, additional, Farani, Marzieh Ramezani, additional, Fateh, Sahand Tehrani, additional, Fateh, Sepand Tehrani, additional, Fatehi, Dorin, additional, Ghorbani-Bidkorpeh, Fatemeh, additional, Gibbens-Bandala, Brenda, additional, Goshtasbi, Nazanin, additional, Gunduz, Oguzhan, additional, Haeri, Azadeh, additional, Hakimi, Fatemeh, additional, Hamidi, Mehrdad, additional, Hashemi, Atieh, additional, Hassan, Moustapha, additional, Hojjati, Saba, additional, Hosseinabadi, Tahereh, additional, Hosseinpour-Moghadam, Reza, additional, Huh, Yun Suk, additional, Imani, Mahsa, additional, Ipek, Tuba Canak, additional, Jabbari, Farzaneh, additional, Jahani, Reza, additional, Jounaki, Kamyar, additional, Kakavand, Melika, additional, Karami, Kimiya, additional, Karslı, Seher, additional, Katerere, David R., additional, Kaushik, Ajeet, additional, Khajeamiri, Yasaman, additional, Khan, Sofia, additional, Khoramipour, Mahsa, additional, Khoskam, Maryam, additional, Koyuncuoglu, Rumeysa, additional, Kumar, Anuj, additional, Kumar, Govindarajan V., additional, Kumar, Krishan, additional, Kumari, Sonika, additional, Lalebeigi, Farnaz, additional, Lim, Vuanghao, additional, Lotfi, Malihe, additional, Lotfi, Mohammad Javad, additional, Mahata, Manoj Kumar, additional, Makwikwi, Tendai, additional, Maleki, Ali, additional, Maleki, Aziz, additional, Maleksabet, Hanieh, additional, Manicum, Amanda-Lee E., additional, Masoumi, Niloofar, additional, Mehryab, Fatemeh, additional, Meléndez-Alafort, Laura, additional, Merati, Faezeh, additional, Mirshafiyan, Mahshad, additional, Moammeri, Ali, additional, Mohit, Elham, additional, Moradi, Ashkan, additional, Mortazavi, Seyed Alireza, additional, Mortazavi, Seyedeh Maryam, additional, Mosayebnia, Mona, additional, Mostafavi, Ebrahim, additional, Movahed, Mahsa Azami, additional, Naderi, Nooshin, additional, Naei, Vahid Yaghoubi, additional, Namazifard, Saina, additional, Nasiri, Azadeh, additional, Nasri, Negar, additional, Nazari, Hojjatollah, additional, Nejati, Omid, additional, Noqani, Hesam, additional, Ocampo-García, Blanca, additional, Ozarici, Huseyin Berkay, additional, Özcan-Bülbül, Ece, additional, Preetam, Subham, additional, Rad, Dorsa Morshedi, additional, Ramazani, Ali, additional, Rath, Rajeswari, additional, Reeves, Sheena M., additional, Rezaei, Niloufar, additional, Rostami, Sanaz, additional, Saadatidizaji, Zahra, additional, Sabzini, Mahdi, additional, Sadat, Zahra, additional, Sadighian, Somayeh, additional, Sadri, Bahareh, additional, Sahrayi, Hamidreza, additional, Saleemi, Mansab Ali, additional, Salehi-Najafabadi, Amir, additional, Samadi, Amirmasoud, additional, Sanyal, Rupa, additional, Sarrami Foroushani, Elnaz, additional, Seyedhamzeh, Mohammad, additional, Shamsabadipour, Amin, additional, Sharma, Ajay, additional, Sharma, Anil Kumar, additional, Sharma, Anirudh, additional, Sharma, Saurabh, additional, Sharma, Varruchi, additional, Singh, Jasdeep, additional, Song, Yo Han, additional, Soni, Savita, additional, Sood, Ankur, additional, Subudhi, P. Debishree, additional, Tabarzad, Maryam, additional, Tabatabaei, Mahsa Seyed, additional, Taghizadeh, Fatemeh, additional, Tayebi, Lobat, additional, Ulag, Songul, additional, Uyar, Perihan, additional, Vosough, Massoud, additional, Warkiani, Majid Ebrahimi, additional, Yavari, Maryam, additional, Yaşayan, Gökçen, additional, Yildiz, Irem, additional, Zare, Iman, additional, Zare, Mohammad Reza, additional, Zarepour, Atefeh, additional, Zarkesh, Ibrahim, additional, and Zarrabi, Ali, additional

Published
2024
Full Text
View/download PDF

13. X‑ray-Based Techniques to Study the Nano–Bio Interface

Author

Sanchez-Cano, Carlos, Alvarez-Puebla, Ramon A, Abendroth, John M, Beck, Tobias, Blick, Robert, Cao, Yuan, Caruso, Frank, Chakraborty, Indranath, Chapman, Henry N, Chen, Chunying, Cohen, Bruce E, Conceição, Andre LC, Cormode, David P, Cui, Daxiang, Dawson, Kenneth A, Falkenberg, Gerald, Fan, Chunhai, Feliu, Neus, Gao, Mingyuan, Gargioni, Elisabetta, Glüer, Claus-C, Grüner, Florian, Hassan, Moustapha, Hu, Yong, Huang, Yalan, Huber, Samuel, Huse, Nils, Kang, Yanan, Khademhosseini, Ali, Keller, Thomas F, Körnig, Christian, Kotov, Nicholas A, Koziej, Dorota, Liang, Xing-Jie, Liu, Beibei, Liu, Sijin, Liu, Yang, Liu, Ziyao, Liz-Marzán, Luis M, Ma, Xiaowei, Machicote, Andres, Maison, Wolfgang, Mancuso, Adrian P, Megahed, Saad, Nickel, Bert, Otto, Ferdinand, Palencia, Cristina, Pascarelli, Sakura, Pearson, Arwen, Peñate-Medina, Oula, Qi, Bing, Rädler, Joachim, Richardson, Joseph J, Rosenhahn, Axel, Rothkamm, Kai, Rübhausen, Michael, Sanyal, Milan K, Schaak, Raymond E, Schlemmer, Heinz-Peter, Schmidt, Marius, Schmutzler, Oliver, Schotten, Theo, Schulz, Florian, Sood, AK, Spiers, Kathryn M, Staufer, Theresa, Stemer, Dominik M, Stierle, Andreas, Sun, Xing, Tsakanova, Gohar, Weiss, Paul S, Weller, Horst, Westermeier, Fabian, Xu, Ming, Yan, Huijie, Zeng, Yuan, Zhao, Ying, Zhao, Yuliang, Zhu, Dingcheng, Zhu, Ying, and Parak, Wolfgang J

Subjects
Medical Biotechnology, Biomedical and Clinical Sciences, Physical Sciences, Biotechnology, Nanotechnology, Bioengineering, Generic health relevance, Lasers, Nanoparticles, Radiography, Synchrotrons, X-Rays, nano-bio interface, X-ray techniques, synchrotron radiation, imaging, nanoparticles, delivery, degradation, spectroscopy, nano−bio interface, Nanoscience & Nanotechnology
Abstract

X-ray-based analytics are routinely applied in many fields, including physics, chemistry, materials science, and engineering. The full potential of such techniques in the life sciences and medicine, however, has not yet been fully exploited. We highlight current and upcoming advances in this direction. We describe different X-ray-based methodologies (including those performed at synchrotron light sources and X-ray free-electron lasers) and their potentials for application to investigate the nano-bio interface. The discussion is predominantly guided by asking how such methods could better help to understand and to improve nanoparticle-based drug delivery, though the concepts also apply to nano-bio interactions in general. We discuss current limitations and how they might be overcome, particularly for future use in vivo.

Published
2021

19. Exploring the Intracellular Distribution of Se Compounds Delivered by Biodegradable Polyelectrolyte Capsules Using X‐Ray Fluorescence Imaging.

Author

Skiba, Marvin, Reszegi, Rebeka R., Huang, Yalan, Roy, Sathi, Han, Jili, Brückner, Dennis, Sanchez‐Cano, Carlos, Zhao, Ying, Hassan, Moustapha, Feliu, Neus, Falkenberg, Gerald, and Parak, Wolfgang J.

Subjects
SELENIUM compounds, INTRACELLULAR tracking, CYTOTOXINS, DRUG development, FLUORESCENCE
Abstract

Selenium (Se) compounds hold promise as potential therapeutics for cancer due to their diverse biological functions and redox‐regulating properties. In this study, the encapsulation of a hydrophobic selenium compound inside 5 µm sized biodegradable polyelectrolyte capsules consisting of poly‐L‐arginine and dextran is investigated. While the encapsulated form of the compound showed comparable cellular uptake and cytotoxicity as the free drug, e.g. no improved anti‐cancer efficacy is achieved, the investigation yielded crucial insights. Utilizing subcellular resolution synchrotron X‐ray fluorescence imaging (XFI), the intracellular location of the Se compound is successfully visualized by demonstrating the degradation of the capsules and the following redistribution of the compound, without exogenous labeling. By applying a quantitative fitting approach, the intracellular Se mass is determined to be 0.09 ± 0.01 pg after degradation of the carrier. This highlights the potential of XFI as a powerful tool for tracking intracellular dynamics of metal‐based drugs, which may facilitate drug development in the clinic. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

21. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Author

Bognàr, Tim, Bartelink, Imke H., Egberts, Toine C.G., Rademaker, Carin M.A., Versluys, A. Birgitta, Slatter, Mary A., Kletzel, Morris, Nath, Christa E., Cuvelier, Geoffrey D.E, Savic, Rada M., Dvorak, Christopher, Long-Boyle, Janel R., Cowan, Morton J., Bittencourt, Henrique, Bredius, Robbert G.M., Güngör, Tayfun, Shaw, Peter J., Ansari, Marc, Hassan, Moustapha, Krajinovic, Maja, Hempel, Georg, Marktel, Sarah, Chiesa, Robert, Théoret, Yves, Lund, Troy, Orchard, Paul J., Wynn, Robert F., Boelens, Jaap Jan, and Lalmohamed, Arief

Published
2022
Full Text
View/download PDF

25. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis

Author

Felber, Matthias, Steward, Colin G., Kentouche, Karim, Fasth, Anders, Wynn, Robert F., Zeilhofer, Ulrike, Haunerdinger, Veronika, Volkmer, Benjamin, Prader, Seraina, Gruhn, Bernd, Ehl, Stephan, Lehmberg, Kai, Müller, Daniel, Gennery, Andrew R., Albert, Michael H., Hauck, Fabian, Rao, Kanchan, Veys, Paul, Hassan, Moustapha, Lankester, Arjan C., Schmid, Jana Pachlopnik, Hauri-Hohl, Mathias M., and Güngör, Tayfun

Published
2020
Full Text
View/download PDF

28. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis

Author

Bartelink, Imke H, Lalmohamed, Arief, van Reij, Elisabeth ML, Dvorak, Christopher C, Savic, Rada M, Zwaveling, Juliette, Bredius, Robbert GM, Egberts, Antoine CG, Bierings, Marc, Kletzel, Morris, Shaw, Peter J, Nath, Christa E, Hempel, George, Ansari, Marc, Krajinovic, Maja, Théorêt, Yves, Duval, Michel, Keizer, Ron J, Bittencourt, Henrique, Hassan, Moustapha, Güngör, Tayfun, Wynn, Robert F, Veys, Paul, Cuvelier, Geoff DE, Marktel, Sarah, Chiesa, Robert, Cowan, Morton J, Slatter, Mary A, Stricherz, Melisa K, Jennissen, Cathryn, Long-Boyle, Janel R, and Boelens, Jaap Jan

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Transplantation, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Area Under Curve, Busulfan, Child, Child, Preschool, Cohort Studies, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Graft Rejection, Graft Survival, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Infant, Male, Recurrence, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

BackgroundIntravenous busulfan combined with therapeutic drug monitoring to guide dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT). The best method to estimate busulfan exposure and optimum exposure in children or young adults remains unclear. We therefore assessed three approaches to estimate intravenous busulfan exposure (expressed as cumulative area under the curve [AUC]) and associated busulfan AUC with clinical outcomes in children or young adults undergoing allogeneic HCT.MethodsIn this retrospective analysis, patients from 15 centres in the Netherlands, USA, Canada, Switzerland, UK, Italy, Germany, and Australia who received a busulfan-based conditioning regimen between March 18, 2001, and Feb 12, 2015, were included. Cumulative AUC was calculated by numerical integration using non-linear mixed effect modelling (AUCNONMEM), non-compartmental analysis (AUC from 0 to infinity [AUC0-∞] and to the next dose [AUC0-τ]), and by individual centres using various approaches (AUCcentre). The main outcome of interest was event-free survival. Other outcomes of interest were graft failure or relapse, or both; transplantation-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host disease [GvHD]); chronic GvHD; overall survival; and chronic-GvHD-free event-free survival. We used propensity-score-adjusted Cox proportional hazard models, Weibull models, and Fine-Gray competing risk regressions for statistical analyses.Findings790 patients were enrolled, 674 of whom were included: 274 (41%) with malignant and 400 (59%) with non-malignant disease. Median age was 4·5 years (IQR 1·4-10·7). The median busulfan AUCNONMEM was 74·4 mg × h/L (95% CI 31·1-104·6), which correlated with the standardised method AUC0-∞ (r2=0·74), but the latter correlated poorly with AUCcentre (r2=0·35). Estimated 2-year event-free survival was 69·7% (95% CI 66·2-73·0). Event-free survival at 2 years was 77·0% (95% CI 72·1-82·9) in the 257 patients with an optimum intravenous busulfan AUC of 78-101 mg × h/L compared with 66·1% (60·9-71·4) in the 235 patients at the low historical target of 58-86 mg × h/L and 49·5% (29·2-66·0) in the 44 patients with a high (>101 mg × h/L) busulfan AUC (p=0·011). Compared with the low AUC group, graft failure or relapse occurred less frequently in the optimum AUC group (hazard ratio [HR] 0·57, 95% CI 0·39-0·84; p=0·0041). Acute toxicity (HR 1·69, 1·12-2·57; p=0·013) and transplantation-related mortality (2·99, 1·82-4·92; p101 mg × h/L) than in the low AUC group (

Published
2016

29. Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation

Author

Santos Carreira, Abel, Salas, Maria Queralt, Remberger, Mats, Novitzky-Basso, Igor, Law, Arjun Datt, Lam, Wilson, Pasic, Ivan, Mazzulli, Tony, Cserti-Gazdewich, Christine, Kim, Dennis (Dong Hwan), Michelis, Fotios V., Viswabandya, Auro, Gerbitz, Armin, Lipton, Jeffrey Howard, Kumar, Rajat, Hassan, Moustapha, and Mattsson, Jonas

Published
2023
Full Text
View/download PDF

32. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement

Author

McCune, Jeannine S., Quinones, Christine M., Ritchie, James, Carpenter, Paul A., van Maarseveen, Erik, Yeh, Rosa F., Anasetti, Claudio, Boelens, Jaap J., Hamerschlak, Nelson, Hassan, Moustapha, Kang, Hyoung Jin, Kanda, Yoshinobu, Paci, Angelo, Perales, Miguel-Angel, Shaw, Peter J., Seewaldt, Victoria L., Savani, Bipin N., Hsieh, Angela, Poon, Betsy, Mohty, Mohamad, Pulsipher, Michael A., Pasquini, Marcelo, and Dupuis, L. Lee

Published
2019
Full Text
View/download PDF

36. Wharton's Jelly mesenchymal stem cell‐derived extracellular vesicles induce liver fibrosis‐resolving phenotype in alternatively activated macrophages.

Author

Torabi, Shukoofeh, Zarrabi, Morteza, Shekari, Faezeh, Poorkazem, Hedie, Lotfinia, Majid, Bencina, Stefan, Gramignoli, Roberto, Hassan, Moustapha, Najimi, Mustapha, and Vosough, Massoud

Subjects
CORD blood, HEPATIC fibrosis, MESENCHYMAL stem cells, EXTRACELLULAR vesicles, STROMAL cells
Abstract

The potential of extracellular vesicles (EVs) isolated from mesenchymal stromal cells in guiding macrophages toward anti‐inflammatory immunophenotypes, has been reported in several studies. In our study, we provided experimental evidence of a distinctive effect played by Wharton Jelly mesenchymal stromal cell‐derived EVs (WJ‐EVs) on human macrophages. We particularly analyzed their anti‐inflammatory effects on macrophages by evaluating their interactions with stellate cells, and their protective role in liver fibrosis. A three‐step gradient method was used to isolate monocytes from umbilical cord blood (UCB). Two subpopulations of WJ‐EVs were isolated by high‐speed (20,000 g) and differential ultracentrifugation (110,000 g). Further to their characterization, they were designated as EV20K and EV110K and incubated at different concentrations with UCB‐derived monocytes for 7 days. Their anti‐fibrotic effect was assessed by studying the differentiation and functional levels of generated macrophages and their potential to modulate the survival and activity of LX2 stellate cells. The EV20K triggers the polarization of UCB‐derived monocytes towards a peculiar M2‐like functional phenotype more effectively than the M‐CSF positive control. The EV20K treated macrophages were characterized by a higher expression of scavenger receptors, increased phagocytic capacity and production level of interleukin‐10 and transforming growth factor‐β. Conditioned medium from those polarized macrophages attenuated the proliferation, contractility and activation of LX2 stellate cells. Our data show that EV20K derived from WJ‐MSCs induces activated macrophages to suppress immune responses and potentially play a protective role in the pathogenesis of liver fibrosis by directly inhibiting HSC's activation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Chitosan‐coated nanoparticles in innovative cancer bio‐medicine.

Author

Rezaei, Niloufar, Zarkesh, Ibrahim, Fotouhi, Alireza, Alikhani, Hani Keshavarz, Hassan, Moustapha, and Vosough, Massoud

Subjects
CHITOSAN, NANOPARTICLES, CYTOTOXINS, PRODUCTION methods, ANTIBACTERIAL agents, BIODEGRADABLE plastics
Abstract

In the recent decade, nanoparticles (NPs) have had enormous implications in cancer biomedicine, including research, diagnosis, and therapy. However, their broad application still faces obstacles due to some practical limitations and requires further development. Recently, there has been more interest in the coated class of nanoparticles to address those challenges. Chitosan‐coated NPs are simple to produce, biodegradable, biocompatible, exhibit antibacterial activity, and have less cytotoxicity. This study provides an updated and comprehensive overview of the application of chitosan‐coated NPs as a promising class of NPs in cancer biomedicine. Additionally, we discussed chitosan‐coated lipid, metal, and polymer‐based nanoparticles in biomedical applications. Furthermore, different coating methods and production/characterization procedures were reviewed. Moreover, the biological and physicochemical advantages of chitosan‐coated NPs, including facilitated controlled release, greater physicochemical stability, improved cell/tissue interaction, and enhanced bioavailability of medications, were highlighted. Finally, the prospects of chitosan‐coated NPs in cancer biomedicine were discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

Author

Palmer, Jeanne, McCune, Jeannine S., Perales, Miguel-Angel, Marks, David, Bubalo, Joseph, Mohty, Mohamad, Wingard, John R., Paci, Angelo, Hassan, Moustapha, Bredeson, Christopher, Pidala, Joseph, Shah, Nina, Shaughnessy, Paul, Majhail, Navneet, Schriber, Jeff, Savani, Bipin N., and Carpenter, Paul A.

Published
2016
Full Text
View/download PDF

48. Non-destructive testing of nano-silica for enhancing the durability of limestone structures in the Valley of the Kings, Luxor, Egypt

Author

Sallam, Ahmed, Hemeda, Sayed, Hassan, Moustapha, and Khalil, Mona M.E.

Abstract

The Valley of the Kings (KV) is a UNESCO world heritage site with more than thirty tombs that have been opened. Since the first tombs were constructed, at least 24 historical flash flood events have been identified, each of which has contributed to the destruction and deterioration of the tombs. After the floods of 1994, most of these tombs were inundated and damaged. Theban Tomb 109, or TT 109, is an example of one of these significant tombs. This study presents a novel technique which uses computer X-ray tomography (CT scan) as a non-destructive method to capture the morphology of the limestone's internal structure at Tomb 109 (TT 109), as well as the stone's grain texture and the surface features through 3D images and videos. Additionally, this research examines the ability of a nanomixture, consisting of tetraethoxysilane (TEOS) and nanosilica, to consolidate the limestone, which is also a novel approach that this study introduces. It is worth noting that the limestone of Tomb 109 has suffered harsh weather conditions such as groundwater and has been in an unfavourable burial environment, causing geostatic stress which in turn has led to stone abrasion and weakness in its mechanical properties. This study also presents a comprehensive morphological and spectroscopic study to confirm the efficiency of the nanomixture in the consolidation of the limestone structures. A cross-examination method using CT scanning, SEM, and XRF analysis before and after consolidation was employed. The final result shows that the nanomixture significantly enhanced the physical and mechanical properties of the limestone., Conservation Science in Cultural Heritage, Vol. 22 (2022)

Published
2023
Full Text
View/download PDF

49. Correction: Asadian et al. Rhenium Perrhenate (188 ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11 , 305.

Author

Asadian, Samieh, Piryaei, Abbas, Gheibi, Nematollah, Aziz Kalantari, Bagher, Reza Davarpanah, Mohamad, Azad, Mehdi, Kapustina, Valentina, Alikhani, Mehdi, Moghbeli Nejad, Sahar, Keshavarz Alikhani, Hani, Mohamadi, Morteza, Shpichka, Anastasia, Timashev, Peter, Hassan, Moustapha, and Vosough, Massoud

Subjects
CELL survival, CYTOTOXINS, LIVER cells, LIVER cancer, CANCER cells
Abstract

This document is a correction notice for an article titled "Rhenium Perrhenate (188 ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells." The correction addresses an error in Figure 1A of the original publication, where two images were unintentionally repeated and the control figures overlapped. The corrected figure has been provided, and the authors state that the scientific conclusions remain unaffected. The original publication has been updated accordingly. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results